Difference between revisions of "Dosulepine-moclobemide"

From Psychiatrienet
Jump to: navigation, search
Line 10: Line 10:
 
* '''Day 8-14:''' a wash-out period of one week is necessary.
 
* '''Day 8-14:''' a wash-out period of one week is necessary.
 
* '''Day 15:''' start administration of moclobemide in a dosage of 150 mg/day.
 
* '''Day 15:''' start administration of moclobemide in a dosage of 150 mg/day.
* '''Day 18:''' increase dosage of moclobemide to 300 mg/day.}}
+
* '''Day 18:''' increase dosage of moclobemide to 300 mg/day.
 +
|info=
 +
{{review}}
 +
 
 +
 
 +
}}

Revision as of 16:45, 28 October 2015

dosulepin
Type antidepressant
Group TCA
links
ATC-code N06AA16
PubChem 13473
PubMed dosulepin
Kompas (Dutch) dosulepin
Wikipedia dosulepin
Moclobemide
Type Antidepressant
Group MAO-I
links
Medscape Moclobemide
PubChem 4235
PubMed Moclobemide
Kompas (Dutch) Moclobemide
Wikipedia Moclobemide

Switch medication from dosulepine to moclobemide.

Nietinrijdenbord.png Stop dosulepine
  • Before day 1: gradually reduce dosage of dosulepine to a maximum of 75 mg/ day, when this dosage is > 75 mg/day.
  • Day 1-3: reduce dosage of dosulepine to 50 mg/day.
  • Day 4-7: reduce dosage of dosulepine to 25 mg/day.
  • Day 8: stop administration of dosulepine.
Eenrichtingbord.png Start moclobemide
  • Day 8-14: a wash-out period of one week is necessary.
  • Day 15: start administration of moclobemide in a dosage of 150 mg/day.
  • Day 18: increase dosage of moclobemide to 300 mg/day.
Infobord.png More information
  • This switch is currently being reviewed.
  1. 1.0 1.1 1.2 1.3 1.4 KNMP; Informatorium Medicamentorum 2015; Monografie "dosulepine" (Dutch)
  2. NVZA; Toxicology.org; Monografie 63 (dutch)
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.